Navigation Links
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Date:1/13/2009

dhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the relevance of EpCAM as a drug target, the efficacy and intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "could," "may," "appear," "promising," "potential," "planned," or the negative of those words or other similar words to be uncertain
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
2. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
3. Wound Management Technologies, Inc. Announces a Published Case Study
4. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
5. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
8. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
9. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Connecticut Center ... organization based in East Hartford, Conn., was awarded a ... II of a project that will determine the feasibility ... rural north-central Connecticut. USDA Rural Development provided $53,000 for ... for the second phase of the feasibility study in ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing ... round of seed financing from friends and family investors. ... develop a novel sustained-release product for ophthalmology. , "We ... their commitment to this important work," said Dr. Ken ... of many areas in which innovations in drug delivery ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ... received final approval from the,United States (U.S.) Food ... Application (ANDA) for albuterol sulfate inhalation solution in,the ... been awarded 180,days of marketing exclusivity for being ...
... Huge Opportunity Exists for Development of More Effective Therapies ... Report from Decision Resources, WALTHAM, Mass., Sept. 26 ... advisory firms for pharmaceutical and,healthcare issues, finds that the ... Genesys, will be the key factor driving the,pancreatic cancer ...
... PALO ALTO, Calif., Sept. 26 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... New York, NY on October 8,2007 at 8:00 ... the presentation may be accessed by visiting the,Investors ...
Cached Biology Technology:Watson Receives FDA Approval for Generic Accuneb(R) 2Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016 2
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... group of researchers from the University of Helsinki and ... to reproduce in mice morphological changes which have taken ... modifications in the embryonic development of mice teeth, induced ... are very similar to those observed in the fossil ... of years ago. , To modify the development ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Conservation scientists asking wrong questions on climate change impacts on wildlife 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... 2007) Where does the benefit lie in an afternoon nap" ... taking a snooze" Researchers in the United Kingdom have ... where beneficial cardiovascular changes take place. This finding ... Function During the Onset Period of Daytime Sleep: Comparison to ...
... illicit drug worldwide and the illegal drug most frequently ... EU countries during the 1990s, in particular among young ... 15- to 24-year-olds, with lifetime prevalence ranging for most ... has been a new surge in the level of ...
... CA, October 13, 2007Today at the Prostate Cancer Foundations ... how eating common foods such as tomatoes and fish, ... high temperatures may help prevent prostate cancer, and help ... in six men will be diagnosed with prostate cancer ...
Cached Biology News:Expecting an afternoon nap can reduce blood pressure 2Expecting an afternoon nap can reduce blood pressure 3The endocannabinoids: Functional roles and therapeutic opportunities 2The endocannabinoids: Functional roles and therapeutic opportunities 3The endocannabinoids: Functional roles and therapeutic opportunities 4Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Digest Medium (TSB), USP is a highly ... general laboratory use. Due to the inclusion ... medium will support growth of many fastidious ... , Product conforms to United States Pharmacopeia ...
... and endothelial cells-directed transfection reagent ... peptide-conjugated polyethylenimine which allows targeted ... and endothelial cells. Integrins are ... and cell-matrix adhesion processes. Many ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
Biology Products: